NOW APPROVED

Help adults with anti-AChR Ab+ gMG1

Take Charge

Introducing the first and only self-administered C5 complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.1

View press release

Help adults with anti-AChR Ab+ gMG1

Take Charge

Introducing the first and only self-administered C5 complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.1

View press release

Ab+=antibody positive.

Be the first to receive important
information about ZILBRYSQ

 

Sign up for news from UCB—an innovator in gMG care

Thank you for your interest in ZILBRYSQ. Please complete the form below to get important information about this new treatment delivered right to your inbox.

*Indicates required field

*Specialty
(check all that apply)
What patient gMG subtypes do you treat?
ZILBRYSQ is indicated only for anti-AChR-positive gMG.
(check all that apply)

I agree that UCB and its business partners may contact me via email regarding UCB treatments, products, and services for informational purposes. I understand that by providing my email address, I am authorized to provide the consent to have emails about the above topics sent to this email address.

At any time, you may unsubscribe from the emailing list, as well as review the Privacy Policy. View full Terms of Use.

Reference:

  1. ZILBRYSQ [Prescribing Information]. Smyrna, GA: UCB, Inc.